Sato, Junko http://orcid.org/0000-0002-9784-5362
Nakajima, Kenichi
Mita, Tomoya
Koshibu, Mami
Sato, Ayako
Goto, Hiromasa
Ikeda, Fuki
Nishida, Yuya
Aso, Katsumi
Watada, Hirotaka
Clinical trials referenced in this document:
Documents that mention this clinical trial
Protocol of a Prospective Observational Study on Lifestyle and Quality of Life in Adults with Type 1 Diabetes in Japan
https://doi.org/10.1007/s13300-024-01539-0
Funding for this research was provided by:
Japan Diabetes Association (2021 grant)
Ministry of Education, Culture, Sports, Science and Technology in Japan (MEXT KAKENHI Grant JP23K10809)
Article History
Received: 25 December 2023
Accepted: 25 January 2024
First Online: 15 February 2024
Declarations
:
: Junko Sato has received honoraria for lectures for Abbott and for research activities for Dexcom. Hirotaka Watada has received honoraria for lectures for Bayer Pharma Japan, Teijin Pharma Ltd., MSD, Sanofi-Aventis K.K., Novo Nordisk, Nippon Boehringer Ingelheim, Eli Lilly, Sumitomo Pharma, Mitsubishi Tanabe Pharma, Daiichi Sankyo Company, Ltd, Abbott, Kowa Co., Ltd., Taisho Pharmaceutical, Astellas Pharma, Kissei Pharmaceutical Co., Ltd., AstraZeneca K.K., Ono Pharmaceutical Co. Ltd. Sanwa Kagaku, and Takeda Pharmaceuticals, and for research activities for Takeda Pharmaceuticals, Nippon Boehringer Ingelheim, Kissei Pharmaceutical, Novo Nordisk, Mitsubishi Tanabe Pharma, Lifescan Japan, Kyowa Kirin, Sumitomo Pharma, Eli Lilly, Teijin Pharma, Taisho Pharmaceutical, Abbott, Ono Pharmaceutical Co. Ltd., Soiken Inc., Sanwa Kagaku, and Kowa. Other authors declare no conflicts of interest.
: All procedures followed are in accordance with the ethical standards of the responsible committees on human experimentation (institutional and national) and with the 1964 Declaration of Helsinki, as revised in 2013. The protocol was approved by the institutional review boards of Juntendo University and Aso Clinic in compliance with the 1964 Declaration of Helsinki and its later amendments, and current legal regulations in Japan (Juntendo University Ethics Committee Approval Nos. H19-0169, H19-0231; Aso Clinic Ethics Committee Approval Nos. A2020001, A2019002). Written informed consent to participate and for publication had been obtained from all study participants.